Search
For optimal search results, please limit to 2 product keywords
If you are searching for information related to a product:
- For optimal results, please enter at least 2 search terms in addition to product name
- Example: [product name] [search term] [search term]
- Example: Product + clinical trials
- For an exact match, please include search terms in double quotations. For example: "Elevatum"
Diffuse large B-cell lymphoma (DLBCL)
Follicular lymphoma (FL)
Mantle Cell Lymphoma (MCL)
For optimal search results, please limit to 2 product keywords
If you are searching for information related to a product:
- For optimal results, please enter at least 2 search terms in addition to product name
- Example: [product name] [search term] [search term]
- Example: Product + clinical trials
- For an exact match, please include search terms in double quotations. For example: "Elevatum"
The list of publications is not an exhaustive list of published materials on the product. The list of references by data topics is selected per evidence-based medicine criteria.
To browse a full listing of published scientific literature: Visit PubMed
1L Diffuse Large B-cell Lymphoma
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
Tilly H, Morschhauser F, Sehn LH, et al. . N Engl J Med. 2022;386(4):351-363.
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma
Morschhauser F, Salles G, Sehn LH, et al. J Clin Oncol. 2025;43(35):3698-3705.
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study
Tilly H, Morschhauser F, Bartlett NL, et al. Lancet Oncol. 2019;20(7):998-1010.
Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non-Asian patients with previously untreated diffuse large B-cell lymphoma in POLARIX
Liao MZ, Deng R, Gibiansky L, et al. Clin Transl Sci. 2023;16(12):2744-2755.
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial
Song Y, Tilly H, Rai S, et al. Blood. 2023;141(16):1971-1981.
Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study
Hu B, Reagan PM, Sehn LH, et al. Blood Adv. 2025;9(10):2489-2499.
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study
Westin J, Phillips TJ, Mehta A, et al. Blood Adv. 2025;9(10):2461-2472.
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study
Minson A, Verner E, Giri P, et al. J Clin Oncol. 2025;43(23):2595-2605.
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study
Olszewski AJ, Phillips TJ, Hoffmann MS, et al. Blood Adv. 2023;7(20):6055-6065.
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study
Thompson C, Trněný M, Morschhauser F, et al. Blood. 2025:blood.2025028848.
R/R Diffuse Large B-cell Lymphoma
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sehn LH, Herrera AF, Flowers CR, et al. J Clin Oncol. 2020;38(2):155-165.
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data
Sehn LH, Hertzberg M, Opat S, et al. Blood Adv. 2022;6(2):533-543.
Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA
Herrera AF, Tracy S, Croft B, et al. Blood Adv. 2022;6(6):1651-1660.
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
Abrisqueta P, González-Barca E, Panizo C, et al. Lancet Haematol. 2024;11(2):e136-e146.
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial
Budde LE, Olszewski AJ, Assouline S, et al. Nat Med. 2024;30(1):229-239.
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. N Engl J Med. 2022;387(24):2220-2231.
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial
Budde LE, Zhang H, Kim WS, et al. J Clin Oncol. 2025;43(36):3799-3811.
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial
Hutchings M, Sureda A, Bosch F, et al. J Clin Oncol. 2025;43(36):3788-3798.
R/R Follicular Lymphoma
Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
Diefenbach C, Kahl BS, McMillan A, et al. Lancet Haematol. 2021;8(12):e891-e901.
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
Flowers CR, Matasar MJ, Herrera AF, et al. Haematologica. 2024;109(4):1194-1205. Published 2024 Apr 1.
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
Budde LE, Sehn LH, Matasar M, et al. Lancet Oncol. 2022;23(8):1055-1065.
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies
Sehn LH, Bartlett NL, Matasar MJ, et al. Blood. 2025;145(7):708-719.
R/R Mantle Cell Lymphoma
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study
Phillips TJ, Carlo-Stella C, Morschhauser F, et al. J Clin Oncol. 2025;43(3):318-328.
Pharmacokinetics
Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study
Deng R, Gibiansky L, Lu T, et al. CPT Pharmacometrics Syst Pharmacol. 2024;13(6):1055-1066.
Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL-6 levels following administration of the T-cell bispecific engager glofitamab
Djebli N, Parrott N, Jaminion F, O'Jeanson A, Guerini E, Carlile D. CPT Pharmacometrics Syst Pharmacol. 2024;13(3):396-409.
Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab
Frances N, Bacac M, Bray-French K, et al. J Pharm Sci. 2022;111(4):1208-1218.
Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab using physiologically-based pharmacokinetic modeling
Chen Y, Ma F, Jones N, Deng R, Li C, Li CC. CPT Pharmacometrics Syst Pharmacol. 2024;13(2):234-246.
Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma
Bender B, Li CC, Marchand M, et al. Clin Transl Sci. 2024;17(6):e13825.
A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma
Li CC, Bender B, Wilkins J, et al. Clin Pharmacol Ther. 2025;117(2):465-474.
Pharmacoeconomics
US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma
Betts KA, Thuresson PO, Felizzi F, et al. J Comp Eff Res. 2020;9(14):1003-1015.
US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma
Matasar M, Masaquel A, S Ho R, et al. J Med Econ. 2023;26(1):1134-1144.
Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma
Vijenthira A, Kuruvilla J, Crump M, Jain M, Prica A. J Clin Oncol. 2023;41(8):1577-1589.
Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma
Thiruvengadam SK, Saumoy M, Schneider Y, et al. Blood. 2022;140(25):2697-2708.
Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma
Patel KK, Isufi I, Kothari S, Foss F, Huntington S. Leuk Lymphoma. 2020;61(14):3387-3394.
Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States
Mahmoudjafari Z, Li J, Bercaw E, et al. J Med Econ. 2025;28(1):595-604.
Glofitamab results in cost savings versus epcoritamab in relapsed/refractory diffuse large B-cell lymphoma: a total cost of care analysis‡
Mahmoudjafari Z, Di Maio D, Li J, Rosettie KL, Masaquel A. Leuk Lymphoma. 2025;66(8):1457-1464.
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA
Lin SW, Shapouri S, Parisé H, et al. Pharmacoeconomics. 2024;42(5):569-582.
Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States
Matasar M, Sanchez Alvarez J, Parisé H, et al. J Med Econ. 2024;27(1):766-776.
Safety
Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma
Gritti G, Belousov A, Relf J, Dixon M, Tandon M, Komanduri K. Blood Adv. 2024;8(14):3615-3618.
Tocilizumab Dosing for Management of T Cell-Engaging Bispecific Antibody-Related CRS in Patients With R/R B-Cell NHL
Jamois C, Turner DC, Gibiansky L, et al. Clin Pharmacol Ther. 2025;118(4):917-927.
Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed/refractory large B-cell lymphoma
Falchi L, Hutchings M, Carlo-Stella C, et al. Haematologica. 2025;110(4):999-1004.
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
Crombie JL, Graff T, Falchi L, et al. Blood. 2024;143(16):1565-1575.
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial
Matasar M, Bartlett NL, Shadman M, et al. Clin Lymphoma Myeloma Leuk. 2024;24(4):240-253.
Real World Experience
Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma
Maurer MJ, Casulo C, Larson MC, et al. Haematologica. 2024;109(7):2177-2185. Published 2024 Jul 1.
Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma
Bosch F, Kuruvilla J, Vassilakopoulos TP, et al. Clin Lymphoma Myeloma Leuk. 2024;24(2):105-121.
Comparative effectiveness between mosunetuzumab monotherapy clinical trial and real-world data in relapsed/refractory follicular lymphoma in third or subsequent lines of systemic therapy
McGough SF, Shamas N, Wang J, et al. Leuk Lymphoma. 2023;64(14):2269-2278.
Non-Hodgkin Lymphoma
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
Morschhauser F, Flinn IW, Advani R, et al. Lancet Haematol. 2019;6(5):e254-e265.
Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study
Phillips T, Brunvand M, Chen AI, et al. Am J Hematol. 2022;97(1):E24-E27.
Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas
Lynch RC, Poh C, Ujjani CS, et al. Blood Adv. 2023;7(11):2449-2458.
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study
Lasater EA, Amin DN, Bannerji R, et al. Am J Hematol. 2023;98(3):449-463.
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
Budde LE, Assouline S, Sehn LH, et al. J Clin Oncol. 2022;40(5):481-491.
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study
Budde LE, Assouline S, Sehn LH, et al. J Clin Oncol. 2024;42(19):2250-2256.
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas
Schuster SJ, Huw LY, Bolen CR, et al. Blood. 2024;143(9):822-832.
Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma
Yuen S, Phillips TJ, Bannerji R, et al. Am J Hematol. 2024;99(7):1281-1289.
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
Hutchings M, Morschhauser F, Iacoboni G, et al. J Clin Oncol. 2021;39(18):1959-1970.
Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma
Bröske AE, Korfi K, Belousov A, et al. Blood Adv. 2022;6(3):1025-1037.
Operationalization
Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators
Graff T, Flinn I, Sharman JP, et al. Cancer Med. 2025;14(11):e70936.
Seamless Navigation of Bispecific Therapies: Optimizing Management and Outpatient Access With a Focus on Coordination
Mahmoudjafari Z, Ali A, Davis J, Sandahl T, Nachar V, Mancini R. J Adv Pract Oncol. Published online September 11, 2024.
Operationalization and Use of Bispecific T-Cell–Engaging Antibodies in Community Practices: Multidisciplinary Perspectives on Developing Logistics and Workflow for Cytokine Release Syndrome Management
Donnellan W, Lin SW, Abbas J, et al. J Adv Pract Oncol. Published online June 25, 2025.
Outpatient Administration of Bispecific Antibody Therapy for Hematologic Malignancies: A Practical Guide
Rahbari KJ, Mijares RDT, Kennedy K, et al. JCO Oncol Pract. 2025:OP2500652.
Looking for more information?
Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.
Call Us: 1-800-821-8590 Hours: Monday-Friday, 5am-5pm PT